Long Noncoding RNA XIST Promotes Resistance to Lenvatinib in Hepatocellular Carcinoma Cells via Epigenetic Inhibition of NOD2
Journal of Oncology · 18.10.2022 · 2022 · 1-17
DOI: 10.1155/2022/4537343 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Oncology, erschienen am 18.10.2022. Verfasst von Anqi Duan und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Second Department of Biliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Innovation Research Project of Shanghai Science and Technology Commission, Long Voyage Medical Talents Development Program of SMMU and Foundation of Shanghai Municipal Health Commission.
Abstract (Originalsprache)
Background. Hepatocellular carcinoma (HCC) is a severe global health issue that still lacks of effective treatments. Lenvatinib is a novel tyrosine kinase inhibitor (TKI) that has been approved for the treatment of HCC. However, drug resistance is inevitable and limits the clinical application of lenvatinib. Till now, there is still little knowledge about the mechanisms under the resistance to lenvatinib in HCC. Long noncoding RNA (lncRNA) is a group of noncoding RNAs that play essential roles in various physiological activities including the chemoresistance. In the present study, through RNA sequencing, we discovered that lncRNA XIST was upregulated in HCC cells that was insensitive to lenvatinib. Mechanically, we found that lncXIST promotes lenvatinib resistance via activation of EZH2-NOD2-ERK axis in HCC cells. Our data suggest that targeting lncXIST/EZH2/NOD2/ERK axis might be a promising strategy to enhance the efficacy of lenvatinib against HCC cells.
Autor:innen und Institutionen
- The Second Department of Biliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China.
- Department of Dermatology, Changhai Hospital, Second Military Medical University, Shanghai 200438, China.
ORCID-Profile: Anqi Duan, Hui Li, Wenlong Yu, Yongjie Zhang, Lei Yin
Förderung
- Medical Innovation Research Project of Shanghai Science and Technology Commission
- Long Voyage Medical Talents Development Program of SMMU and Foundation of Shanghai Municipal Health Commission
Zitieren
APA
Duan, A., Li, H., Yu, W., Zhang, Y., & Yin, L. (2022). Long Noncoding RNA XIST Promotes Resistance to Lenvatinib in Hepatocellular Carcinoma Cells via Epigenetic Inhibition of NOD2. Journal of Oncology, 2022, 1-17. https://doi.org/10.1155/2022/4537343
Vancouver
Duan A, Li H, Yu W, Zhang Y, Yin L. Long Noncoding RNA XIST Promotes Resistance to Lenvatinib in Hepatocellular Carcinoma Cells via Epigenetic Inhibition of NOD2. Journal of Oncology. 2022;2022:1-17. doi:10.1155/2022/4537343
BibTeX
@article{Duan2022,
author = {Duan, Anqi and Li, Hui and Yu, Wenlong and Zhang, Yongjie and Yin, Lei},
title = {Long Noncoding RNA XIST Promotes Resistance to Lenvatinib in Hepatocellular Carcinoma Cells via Epigenetic Inhibition of NOD2},
journal = {Journal of Oncology},
year = {2022},
volume = {2022},
pages = {1--17},
doi = {10.1155/2022/4537343}
}
EUVIMED